View Older Stories View More Recent Stories

Feb 18, 2021 04:01PM Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Feb 17, 2021 04:01PM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Feb 8, 2021 08:00AM Paratek Announces Expansion of NUZYRA® Launch into the Community Setting
Feb 1, 2021 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan 6, 2021 08:00AM Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
Jan 4, 2021 05:00PM Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group
Dec 1, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 12, 2020 04:01PM Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Nov 5, 2020 04:01PM Paratek Pharmaceuticals Announces Third Quarter 2020 Total Revenue of $13.7 Million
Nov 2, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 27, 2020 08:00AM Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
Oct 21, 2020 08:00AM Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020
Sep 9, 2020 04:01PM Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Sep 1, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 10, 2020 07:30AM Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million
Aug 5, 2020 04:01PM Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
Aug 3, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 28, 2020 04:01PM Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020
May 29, 2020 08:30AM Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
May 28, 2020 08:00AM Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference
May 11, 2020 04:05PM Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
May 11, 2020 06:30AM Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
Apr 30, 2020 08:00AM Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020
Apr 2, 2020 08:08AM Paratek Pharmaceuticals (PRTK) Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA
Apr 2, 2020 08:00AM Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)
Apr 1, 2020 08:05AM Paratek Pharmaceuticals (PRTK) Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of Manufacturing Supply Chain for NUZYRA
Apr 1, 2020 08:00AM Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)
Mar 10, 2020 04:04PM Paratek Pharmaceuticals (PRTK) Announces Submission of pre-Emergency Use Authorization Application to FDA for NUZYRA
Mar 10, 2020 04:01PM Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)
Mar 2, 2020 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb 26, 2020 08:00AM Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Feb 25, 2020 04:01PM Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million
Feb 24, 2020 07:08AM Paratek Pharmaceuticals (PRTK) Announces License Grant to Almirall for SEYSARA for Greater China Region
Feb 24, 2020 07:00AM Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region
Feb 13, 2020 04:01PM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Dec 18, 2019 05:12PM Paratek Pharmaceuticals (PRTK) Says it was Awarded BARDA Project BioShield Contract for NUZYRA
Dec 18, 2019 05:12PM Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
Dec 2, 2019 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 12, 2019 04:05PM Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019
Nov 4, 2019 04:05PM Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
Nov 1, 2019 04:05PM Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 31, 2019 04:47PM Paratek Pharmaceuticals (PRTK) Reports Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
Oct 31, 2019 04:05PM Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
Oct 17, 2019 04:12PM Paratek Pharmaceuticals (PRTK) Announces Withdrawal of EMA Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
Oct 17, 2019 04:05PM Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
Oct 1, 2019 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2019 08:00AM Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
Sep 4, 2019 08:00AM Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Sep 3, 2019 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 30, 2019 08:04AM Paratek Pharmaceuticals (PRTK) Reports Publication of Phase 3 Oral only Dosing Study of NUZYRA (omadacycline) for Skin Infections
View More Recent Stories View Older Stories